Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashDepreciation & Amortization (CF)Free Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther Working Capital ChangesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Nurix Therapeutics (NRIX) Share-based Compensation (2019 - 2025)

Historic Share-based Compensation for Nurix Therapeutics (NRIX) over the last 7 years, with Q4 2025 value amounting to $9.1 million.

  • Nurix Therapeutics' Share-based Compensation rose 679.36% to $9.1 million in Q4 2025 from the same period last year, while for Nov 2025 it was $38.0 million, marking a year-over-year increase of 1189.54%. This contributed to the annual value of $38.0 million for FY2025, which is 1189.54% up from last year.
  • Latest data reveals that Nurix Therapeutics reported Share-based Compensation of $9.1 million as of Q4 2025, which was up 679.36% from $9.8 million recorded in Q3 2025.
  • Nurix Therapeutics' 5-year Share-based Compensation high stood at $10.4 million for Q2 2025, and its period low was $2.7 million during Q1 2021.
  • For the 5-year period, Nurix Therapeutics' Share-based Compensation averaged around $7.5 million, with its median value being $8.4 million (2022).
  • As far as peak fluctuations go, Nurix Therapeutics' Share-based Compensation soared by 143409.09% in 2021, and later tumbled by 777.03% in 2024.
  • Over the past 5 years, Nurix Therapeutics' Share-based Compensation (Quarter) stood at $4.8 million in 2021, then soared by 71.32% to $8.3 million in 2022, then decreased by 3.29% to $8.0 million in 2023, then grew by 6.03% to $8.5 million in 2024, then grew by 6.79% to $9.1 million in 2025.
  • Its Share-based Compensation stands at $9.1 million for Q4 2025, versus $9.8 million for Q3 2025 and $10.4 million for Q2 2025.